



NextGen Ventures 2 Coöperatief U.A.

SFDR-Disclosures

Version 4

July 13, 2026



Contents

0. Version History	3
1. Introduction.....	4
2. Summary	4
3. Disclosure of sustainability information	5



o. Version History

Version number	Publication date	Major changes
Version 1	22 December 2023	Creation document
Version 2	10 March 2025	Review
Version 3	19 Februari 2026	Review
Version 4	13 July 2026	Translation to English

1. Introduction

This document provides information about NextGen Ventures 2 Cooperatief U.A. (the Fund) in relation to the Sustainable Finance Disclosure Regulation (SFDR). This information is legally required and helps provide transparency about sustainability characteristics, objectives and risks.

2. Summary

The Fund promotes environmental and/or social characteristics within the meaning of Article 8 of the SFDR but does not have a sustainable investment objective.

- The Fund invests exclusively in companies expected to have a positive impact on healthcare based on the Quadruple Aim Framework;
- The Fund promotes environmental and/or social safeguards by applying exclusion criteria for products and practices that the Fund considers to have a negative impact on society and that are not compatible with a sustainable investment strategy;
- The Fund promotes compliance with and the conduct of business activities in line with the [United Nations Global Compact \(UNGC\)](#);

The Fund invests in Dutch startups that use technology (hardware) and data (software) to deliver care more efficiently and with better outcomes. The Fund invests at an early stage in the form of equity capital. The Fund can contribute through its specific focus on healthcare, experience in company development and network within the healthcare sector.

The Fund does not invest in products whose business activity (i) is the production of or trade in weapons, (ii) is in the gambling industry, (iii) is in tobacco production or the production or marketing of tobacco products, or (iv) involves animal testing, human cloning and/or genetically modified organisms, insofar as such activities are not in compliance with legislation.

The Fund invests exclusively in products that are in compliance with the E/S characteristics within the meaning of Article 8 of the SFDR.

The Fund has incorporated the sustainability aspects of its investment strategies into due diligence processes and procedures for selection and monitoring. The Fund is primarily responsible for carrying out this due diligence with respect to its strategies.

For its monitoring the Fund relies on the reporting provided by products. The main limitations of the methodology are the lack of adequate information on indicators within the scope and stage of the products and reliance on the accuracy and completeness of the reporting provided by products.

The Fund's interests are subject to the selection process which includes among other things constructive dialogue between Investment Managers and the companies invested in.

3. Disclosure of sustainability information

(b) No sustainable investment objective

The Fund promotes environmental and/or social characteristics but does not have a sustainable investment objective.

The Fund invests exclusively in companies expected to have a positive impact on healthcare based on the Quadruple Aim Framework.

The following adverse effects of investment decisions on sustainability factors are taken into account as an exclusion factor for investments:

- PAI 4: Companies active in the fossil fuel sector;
- PAI 10: Violations of UN Global Compact principles;
- PAI 14: Controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons);

Investments are not aligned with:

- OECD Guidelines for Multinational Enterprises
- UN Guiding Principles on Business and Human Rights
- Eight fundamental conventions identified in the Declaration of the International Labour Organization on fundamental Principles and Rights at Work;
- International Bill of Human Rights.

(c) Environmental or social characteristics of the financial product

The Fund invests from the premise that alongside technological innovation and business operations, attention must also be paid to the societal impact of an innovation. In a positive sense by structurally steering towards societal impact objectives but also by actively managing E/S risks and making this transparent and measurable. The Fund invests exclusively in companies expected to have a positive impact on healthcare based on the Quadruple Aim Framework.

The Fund promotes environmental and/or social characteristics by not investing in products whose business activity (i) is the production of or trade in weapons, (ii) is in the gambling industry, (iii) is in tobacco production or the production or marketing of tobacco products, or (iv) involves animal testing, human cloning and/or genetically modified organisms, insofar as such activities are not in compliance with legislation.

The Fund invests exclusively in products that commit to the United Nations Global Compact (UNGC).

(d) Investment strategy

The Fund invests in Dutch startups that use technology (hardware) and data (software) to deliver care more efficiently and with better outcomes. At this early stage the Fund can contribute through its specific focus on healthcare, experience in company development and network within the healthcare sector.

The Fund includes in the investment documentation of its products a commitment to an "inclusion criterion" whereby for every management position at least one candidate is interviewed from a group that is less represented in the workforce. The product commits to providing information about the UBOs of its shareholders and parties holding a significant interest in the company to its shareholders in the context of KYC/AML.

The Fund is primarily responsible for assessing good governance including matters relating to sound management structures employee relations remuneration of staff involved and compliance with tax legislation.

(e) Proportion of investments

The Fund invests exclusively (100%) in products that are in compliance with the E/S characteristics.

(f) Monitoring of environmental or social characteristics

The Fund monitors the following adverse effects of investment decisions on E/S factors annually:

- PAI 2: Carbon footprint;
- PAI 13: Board gender diversity;
- Standardised methodologies for monitoring the healthcare impact of the type of companies (scope, stage) invested in are lacking. The Fund therefore agrees Key Performance Indicators (KPIs) upon investing in a company that are relevant to the scope, stage and impact based on the Quadruple Aim Framework (better health outcomes, lower healthcare costs, improved patient experience of care and improved professional experience for healthcare workers).

(g) Methodologies

The Fund monitors the following at product level annually:

- PAI 2: Carbon footprint;
 - o CO2 footprint based on total operational floor area (m2) and number of company vehicles.
- PAI 13: Board gender diversity
 - o Proportion of women in board and executive roles within the company.
- Company specific KPIs for the scope, stage and impact based on the Quadruple Aim Framework (better health outcomes, lower healthcare costs, improved patient experience of care and improved professional experience for healthcare workers). Examples include number of users in healthcare, number of procedures performed, percentage cost reduction.

Reporting on impact takes place annually in the annual report at company level.

(h) Data sources and processing

The Fund relies for its due diligence and monitoring on public sources constructive dialogues with its products and reporting provided by products. Companies invested in are at an early stage and generally have limited business operations. Data is processed in the annual report. Data can be produced accurately (>95% accuracy; 5% estimation).

(i) Methodological and data limitations

The main limitations of the methodology are the lack of adequate information on indicators within the scope and stage of the products and reliance on the accuracy and completeness of the reporting provided by products. The methodological and data limitations do not affect the way in which the promoted environmental and/or social characteristics are monitored.

(j) Due diligence



The Fund is primarily responsible for carrying out due diligence research with respect to its strategies. External input from experts in financial legal medical and technological matters is determined on a case by case basis. There is no external verification of due diligence reporting.

(k) Engagement policy

The Fund's interests are subject to the selection process and monitoring policy which includes among other things constructive dialogue between the Fund and the companies invested in. The Fund participates as shareholder and depending on the participation in advisory boards, supervisory boards or oversight bodies.